Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Aaron T. Scott,Michelle Weitz,Patrick Breheny,Po Hien Ear,Benjamin W. Darbro,Benjamin W. Darbro,Bartley Brown,Terry A. Braun,Guiying Li,Shaikamjad Umesalma,Courtney A. Kaemmer,Chandra K. Maharjan,Dawn E. Quelle,Dawn E. Quelle,Andrew M. Bellizzi,Andrew M. Bellizzi,Chandrikha Chandrasekharan,Chandrikha Chandrasekharan,Joseph S. Dillon,Joseph S. Dillon,Thomas M. O'Dorisio,Thomas M. O'Dorisio,James R. Howe,James R. Howe +23 more
Reads0
Chats0
TLDR
The potential utility of these drugs was confirmed by in vitro cytotoxicity assays, suggesting drugs targeting MEK and TOP2A may be highly efficacious against metastatic pNETs.Abstract:
Purpose: Pancreatic neuroendocrine tumors (pNETs) are uncommon malignancies noted for their propensity to metastasize and comparatively favorable prognosis. Although both the treatment options and clinical outcomes have improved in the past decades, most patients will die of metastatic disease. New systemic therapies are needed. Experimental Design: Tissues were obtained from 43 patients with well-differentiated pNETs undergoing surgery. Gene expression was compared between primary tumors versus liver and lymph node metastases using RNA-Seq. Genes that were selectively elevated at only one metastatic site were filtered out to reduce tissue-specific effects. Ingenuity pathway analysis (IPA) and the Connectivity Map (CMap) identified drugs likely to antagonize metastasis-specific targets. The biological activity of top identified agents was tested in vitro using two pNET cell lines (BON-1 and QGP-1). Results: A total of 902 genes were differentially expressed in pNET metastases compared with primary tumors, 626 of which remained in the common metastatic profile after filtering. Analysis with IPA and CMap revealed altered activity of factors involved in survival and proliferation, and identified drugs targeting those pathways, including inhibitors of mTOR, PI3K, MEK, TOP2A, protein kinase C, NF-kB, cyclin-dependent kinase, and histone deacetylase. Inhibitors of MEK and TOP2A were consistently the most active compounds. Conclusions: We employed a complementary bioinformatics approach to identify novel therapeutics for pNETs by analyzing gene expression in metastatic tumors. The potential utility of these drugs was confirmed by in vitro cytotoxicity assays, suggesting drugs targeting MEK and TOP2A may be highly efficacious against metastatic pNETs. This is a promising strategy for discovering more effective treatments for patients with pNETs.read more
Citations
More filters
Journal ArticleDOI
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Petros Grivas,Amir Mortazavi,Joel Picus,Noah M. Hahn,Matthew I. Milowsky,Lowell L. Hart,Ajjai Alva,Joaquim Bellmunt,Sumanta K. Pal,Richard Martin Bambury,Peter H. O'Donnell,Sumati Gupta,Elizabeth A. Guancial,Guru Sonpavde,Demiana Faltaos,Diane Potvin,James G. Christensen,Richard C. Chao,Jonathan E. Rosenberg +18 more
TL;DR: The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and E1A binding protein p300 [EP300] histone acetyltransferase genes in a single‐arm, open‐label phase 2 study.
Journal ArticleDOI
Topoisomerase II inhibitors in AML: past, present, and future.
TL;DR: The authors believe that small molecule inhibitors, such as venetoclax and possibly immunotherapy options could also be incorporated to the treatment paradigm in selected patients.
Journal ArticleDOI
Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
Anja Rinke,Christoph J. Auernhammer,Lisa Bodei,Mark Kidd,Sebastian Krug,Rita T. Lawlor,Ilaria Marinoni,Aurel Perren,Aldo Scarpa,Halfdan Sorbye,Marianne Pavel,Matthias M. Weber,Irvin M. Modlin,Thomas M. Gress +13 more
TL;DR: In this article, a review of advances in NEN research and delineates the current status of translation with a view to laying the basis for a genome-based personalised medicine management of advanced GEPNEN.
Journal ArticleDOI
Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.
Chandra K. Maharjan,Po Hien Ear,Catherine G Tran,James R. Howe,Chandrikha Chandrasekharan,Dawn E. Quelle +5 more
TL;DR: In this article, a review examines the known molecular alterations associated with pancreatic neuroendocrine tumor pathogenesis, identifying which changes may be drivers of the disease and, as such, relevant therapeutic targets.
Journal ArticleDOI
The Clinical Features and Molecular Mechanisms of ACTH-secreting Pancreatic Neuroendocrine Tumors.
Cui Zhang,Jiabin Jin,Jing Xie,Lei Ye,Tingwei Su,Lei Jiang,Weiwei Zhou,Yiran Jiang,Luming Wu,Ting Wang,Xu Zhong,Guang Ning,Baiyong Shen,Weiqing Wang +13 more
TL;DR: This study aimed to elucidate the clinical features and molecular mechanisms of pNETs with EAS by methylation analysis and further supplements the genetic features of ACTH-secreting NETs.
References
More filters
Journal ArticleDOI
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
TL;DR: This work presents DESeq2, a method for differential analysis of count data, using shrinkage estimation for dispersions and fold changes to improve stability and interpretability of estimates, which enables a more quantitative analysis focused on the strength rather than the mere presence of differential expression.
Journal ArticleDOI
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Mihaela Pertea,Geo Pertea,Corina Antonescu,Tsung Cheng Chang,Joshua T. Mendell,Steven L. Salzberg +5 more
TL;DR: StringTie, a computational method that applies a network flow algorithm originally developed in optimization theory, together with optional de novo assembly, to assemble these complex data sets into transcripts produces more complete and accurate reconstructions of genes and better estimates of expression levels.
Journal ArticleDOI
Salmon provides fast and bias-aware quantification of transcript expression
TL;DR: Salmon is the first transcriptome-wide quantifier to correct for fragment GC-content bias, which substantially improves the accuracy of abundance estimates and the sensitivity of subsequent differential expression analysis.
Journal ArticleDOI
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Charity W. Law,Charity W. Law,Yunshun Chen,Yunshun Chen,Wei Shi,Wei Shi,Gordon K. Smyth,Gordon K. Smyth +7 more
TL;DR: New normal linear modeling strategies are presented for analyzing read counts from RNA-seq experiments, and the voom method estimates the mean-variance relationship of the log-counts, generates a precision weight for each observation and enters these into the limma empirical Bayes analysis pipeline.
Journal ArticleDOI
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
James C. Yao,Manal M. Hassan,Alexandria T. Phan,Cecile G. Dagohoy,Colleen Leary,Jeannette E. Mares,Eddie K. Abdalla,Jason B. Fleming,Jean Nicolas Vauthey,Asif Rashid,Douglas B. Evans +10 more
TL;DR: Clinicians need to be become familiar with the natural history and patterns of disease progression, which are characteristic of these tumors, suggesting that NETs are more prevalent than previously reported.
Related Papers (5)
Daxx/atrx, men1, and mtor pathway genes are frequently altered in pancreatic neuroendocrine tumors
Whole-genome landscape of pancreatic neuroendocrine tumours
Aldo Scarpa,David K. Chang,Katia Nones,Katia Nones,Vincenzo Corbo,Ann-Marie Patch,Ann-Marie Patch,Peter Bailey,Peter Bailey,Rita T. Lawlor,Amber L. Johns,David Miller,Andrea Mafficini,Borislav Rusev,Maria Scardoni,Davide Antonello,Stefano Barbi,Katarzyna O. Sikora,Sara Cingarlini,Caterina Vicentini,Skye McKay,Michael C.J. Quinn,Michael C.J. Quinn,Timothy J. C. Bruxner,Angelika N. Christ,Ivon Harliwong,Senel Idrisoglu,Suzanne McLean,Craig Nourse,Craig Nourse,Ehsan Nourbakhsh,Peter J. Wilson,Matthew J. Anderson,J. Lynn Fink,Felicity Newell,Felicity Newell,Nick Waddell,Oliver Holmes,Oliver Holmes,Stephen H. Kazakoff,Stephen H. Kazakoff,Conrad Leonard,Conrad Leonard,Scott Wood,Scott Wood,Qinying Xu,Qinying Xu,Shivashankar H. Nagaraj,Eliana Amato,Irene Dalai,Samantha Bersani,Ivana Cataldo,Angelo Paolo Dei Tos,Paola Capelli,Maria Vittoria Davì,Luca Landoni,Anna Malpaga,Marco Miotto,Vicki L. J. Whitehall,Vicki L. J. Whitehall,Barbara A. Leggett,Barbara A. Leggett,Barbara A. Leggett,Janelle L. Harris,Jonathan M. Harris,Marc D. Jones,Jeremy L. Humphris,Lorraine A. Chantrill,Venessa T. Chin,Adnan Nagrial,Marina Pajic,Christopher J. Scarlett,Christopher J. Scarlett,Andreia V. Pinho,Ilse Rooman,Christopher W. Toon,Jianmin Wu,Jianmin Wu,Mark Pinese,Mark J. Cowley,Andrew Barbour,Amanda Mawson,Emily S. Humphrey,Emily K. Colvin,Angela Chou,Angela Chou,Jessica A. Lovell,Nigel B. Jamieson,Nigel B. Jamieson,Fraser Duthie,Marie-Claude Gingras,Marie-Claude Gingras,William E. Fisher,Rebecca A. Dagg,Loretta Lau,Michael Lee,Hilda A. Pickett,Roger R. Reddel,Jaswinder S. Samra,Jaswinder S. Samra,James G. Kench,James G. Kench,James G. Kench,Neil D. Merrett,Neil D. Merrett,Krishna Epari,Nam Q. Nguyen,Nikolajs Zeps,Nikolajs Zeps,Massimo Falconi,Michele Simbolo,Giovanni Butturini,George Van Buren,Stefano Partelli,Matteo Fassan,Kum Kum Khanna,Anthony J. Gill,Anthony J. Gill,David A. Wheeler,Richard A. Gibbs,Elizabeth A. Musgrove,Claudio Bassi,Giampaolo Tortora,Paolo Pederzoli,John V. Pearson,John V. Pearson,Nicola Waddell,Nicola Waddell,Andrew V. Biankin,Sean M. Grimmond +129 more
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond,Laetitia Dahan,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,Denis Smith,Aaron I. Vinik,Jen-Shi Chen,Dieter Hörsch,Pascal Hammel,Bertram Wiedenmann,Eric Van Cutsem,Shem Patyna,Dongrui Ray Lu,C. Blanckmeister,Richard C. Chao,Philippe Ruszniewski +19 more